eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2021
vol. 25
 
Share:
Share:
abstract:
Review paper

What is new about ovarian malignancies?

Kinga Grabska
1
,
Izabela Pilarska
1
,
Marta Magdalena Fudalej
2
,
Andrzej Deptała
2
,
Anna Badowska-Kozakiewicz
2

  1. Students’ Scientific Organization of Cancer Cell Biology, Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland
  2. Department of Cancer Prevention, Medical University of Warsaw, Warsaw, Poland
Contemp Oncol (Pozn) 2021; 25 (4): 225–231
Online publish date: 2021/12/29
View full text Get citation
 
PlumX metrics:
Ovarian cancer is one of the most prevalent pathologies in gynaecology. This malignancy can be divided into 2 large groups: epithelial and non-epithelial. Because epithelial ovarian cancers (EOC) are the most commonly diagnosed, this paper focuses on the latest therapies associated with this disease. Due to the difficult diagnosis, EOC is frequently detected in the advanced stage. The treatment is usually complex and requires specialist knowledge. Advances and new ideas, such as identification of various genes and molecules that can serve as prognostic factors, might increase patients’ chances of survival; they may contribute to optimization of patients’ treatment, deciding whether to use aggressive treatment strategies, and predicting chemoresistance. Moreover, new strategies might also improve the quality of life of patients. The study aimed to analyse and discuss the latest reports on new methods of managing EOC.
keywords:

ovarian cancer, immunotherapy, chemotherapy, epithelial cancer, treatment

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.